Reply to Zhou and Wu, "Be Careful with Adverse Events Caused by Cefoperazone-Sulbactam".

Jien-Wei Liu,Yen-Hsu Chen,Wen-Sen Lee,Jung-Chung Lin,Ching-Tai Huang,Hsi-Hsun Lin,Yung-Ching Liu,Yin-Ching Chuang,Hung-Jen Tang,Yao-Shen Chen,Wen-Chien Ko,Min-Chi Lu,Fu-Der Wang

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY（2020）

引用 0|浏览94

暂无评分

摘要

We thank Drs. Zhou and Wu for their interest in our recent publication entitled “Randomized noninferiority trial of cefoperazone-sulbactam versus cefepime in the treatment of hospital-acquired and health care-associated pneumonia” (1) and appreciate comments they made on it. The recruited patients in this trial were allocated to subpopulations for intent-to treat (ITT), per-protocol (PP), and safety analyses.

查看译文

关键词

adverse events,zhou,cefoperazone-sulbactam

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要